

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Hiv | D006678 | — | O98.7 | — | 1 | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | — | — | — | 1 |
| Drug common name | DEXELVUCITABINE |
| INN | dexelvucitabine |
| Description | Dexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. It is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. that inhibits HIV-1 replication in vitro. During phase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus.
|
| Classification | Small molecule |
| Drug class | nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(=O)n([C@H]2C=C[C@@H](CO)O2)cc1F |
| PDB | — |
| CAS-ID | 134379-77-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL109831 |
| ChEBI ID | — |
| PubChem CID | 64973 |
| DrugBank | — |
| UNII ID | KU8SPJ271W (ChemIDplus, GSRS) |
